Reed Joshua sold $164K of SRRK

Reed Joshua sold 3,053 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.74 ($53.50–$54.28, $0.16M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reed Joshua
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
medium confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The disclosure provides transparency on insider selling activity but does not include new company performance, guidance, or deal information.

02

Market read

Traders may monitor SRRK for broader insider activity, but this specific Form 4 is unlikely to drive a major repricing without additional catalysts.

03

What to watch

The article does not disclose any concurrent buy/sell by other insiders, changes in guidance, or new company events that would contextualize the sale.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-07-06 for trades dated 2026-07-01

Background

The article summarizes an SEC Form 4 insider transaction by a director of Scholar Rock Holding Corp.

Company-level read

Ticker impact

$SRRKNeutralMedium confidence
Context

Scholar Rock Holding director Reed Joshua sold about 3,053 shares in open-market transactions totaling $164,067.43 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal sector read-through; this is company-specific insider activity without disclosed operational or regulatory changes.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations, so traders may ignore it.

Key entities

  • Scholar Rock Holding Corp

    US-listed company whose director filed an SEC Form 4 for open-market share sales under a 10b5-1 plan.

  • Reed Joshua

    Director who sold 3,053 shares totaling $164,067.43 across two trades dated 2026-07-01.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRRKMedAI 8/10

Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript

Scholar Rock (SRRK) reported Q3 2026 earnings, highlighting FDA approval of ISEMBYLD for SMA, a $205M deal for a priority review voucher, and progress in Japan and Phase II FORGE study. ISEMBYLD showed a 2.2-point motor function improvement in trials, with strong early launch demand. The company reported $0.6M in ISEMBYLD revenue and $413.6M in cash, with no immediate need for equity offering.

$SRRKLow

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

Scholar Rock (SRRK) reported Q3 earnings, noting no demand impact from a bone fracture warning. The company resubmitted its European marketing application for apitegromab, expecting a decision in early 2027. It anticipates a 2027 launch in Japan and Germany. Operating expenses were $106.6M, with $413.6M in cash. SRRK sold a priority review voucher for $205M and has access to an additional $150M under its debt facility.

$SRRKHighAI 8/10

Raymond James reiterates Strong Buy on Scholar Rock stock after Q3 results

Raymond James maintained a Strong Buy rating and $72.00 price target for Scholar Rock (NASDAQ: SRRK) after its Q3 2026 results. The stock is up 17% this week and 76% over the past year. Scholar Rock reported its first product revenues for ISEMBYLD, which received FDA approval in September 2026. The company's EPS beat estimates but revenue missed expectations, falling 60.14% short of forecasts.